PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer.
Br J Cancer
; 128(1): 121-129, 2023 01.
Article
in En
| MEDLINE
| ID: mdl-36323880
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
Type of study:
Prognostic_studies
/
Risk_factors_studies
Limits:
Female
/
Humans
Language:
En
Journal:
Br J Cancer
Year:
2023
Document type:
Article
Affiliation country:
China
Country of publication:
United kingdom